FindTrial
Sign In

SUPRAFLEX Cruz

DEVICE2 trials

Sponsors

National University of Ireland, Galway, Ireland, Fundación EPIC

Conditions

Arterial Occlusive DiseasesCardiovascular DiseasesCoronary Artery DiseaseCoronary Artery Disease (CAD)Coronary DiseaseHeart DiseasesIschemic Heart DiseaseMyocardial Ischemia

Unknown Phase

Multivessel TALENT
Active, not recruitingNCT04390672
National University of Ireland, Galway, IrelandArterial Occlusive Diseases, Cardiovascular Diseases, Coronary Artery Disease +4
Start: 2020-09-22End: 2026-09-01Target: 1550Updated: 2026-02-27
SUPRAFLEX CRUZ PMCF Study ( rEpic05 )
RecruitingNCT05617599
Fundación EPICCoronary Artery Disease (CAD), Ischemic Heart Disease
Start: 2023-05-10End: 2026-12-01Target: 508Updated: 2025-12-16

Related Papers

Diffuseness of coronary artery disease impacts on immediate hemodynamic and predicted clinical outcomes.
2025-01-171 citations
Interim prediction of two-year all-cause mortality in patients with de novo multivessel coronary artery disease undergoing intended multivessel PCI
European Heart Journal2023-11-01
Hemodynamic assessment of pci using ultrasonic flow ratio in multivessel cad
European Heart Journal2023-11-01
Minimum stent area, stent expansion and ultrasonic flow ratio post pci: insights from multivessel talent trial
European Heart Journal2023-11-01
The Utility of the SYNTAX Score II and SYNTAX Score 2020 for Identifying Patients with Three-Vessel Disease Eligible for Percutaneous Coronary Intervention in the Multivessel TALENT Trial: A Prospective Pilot Experience
Reviews in Cardiovascular Medicine2022-04-085 citations
A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial
EuroIntervention2020-12-0114 citations